<DOC>
	<DOC>NCT02519348</DOC>
	<brief_summary>This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 (Durvalumab) in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with unresectable hepatocellular carcinoma</brief_summary>
	<brief_title>A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1. Male or female subjects 2. 18 years and older (Japan20 years and older) 3. Confirmed diagnosis of unresectable hepatocellular carcinoma with or without concomitant viral hepatits B or hepatitis C infection. 4. Immunotherapynaive and have either progressed on, are intolerant to, or refused treatment with sorafenib. Subjects who receive treatment with systemic therapies other than sorafenib are not eligible. 1. Prior exposure to immunemediated therapy 2. Hepatic encephalopathy characterized by asterixis 3. Active or prior documented gastrointestinal variceal bleed 4. Ascites requiring nonpharmacologic intervention or escalation in pharmacologic intervention to maintain symptom control 5. Main portal vein thrombosis 6. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment 7. Active or prior documented autoimmune or inflammatory disease with some exceptions 8. Current or prior use of immunosuppressive medication within 14 days with some exceptions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Tremelimumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
</DOC>